Biogipuzkoa
Centro de investigación
![Foto de Biogipuzkoa](/img/uploaded/BB680065D0326B877226AAACFBE7F51A.png)
![Foto de Hospital Sierrallana](/img/noimage_org.png)
Hospital Sierrallana
Torrelavega, EspañaPublicaciones en colaboración con investigadores/as de Hospital Sierrallana (51)
2023
-
A novel clinical sign to assess the risk of Parkinson’s disease in patients with isolated asymmetric arm swing
Neurological Sciences, Vol. 44, Núm. 4, pp. 1401-1404
-
Interactions between functional networks in Parkinson's disease mild cognitive impairment
Scientific Reports, Vol. 13, Núm. 1
-
Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients
Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836
-
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247
-
Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
Frontiers in Immunology, Vol. 14
2022
-
Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review
Rheumatology (Oxford, England), Vol. 61, Núm. 11, pp. 4427-4436
-
Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study
Drugs in Context, Vol. 11
-
Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients
Clinical and Experimental Rheumatology
-
Neurogenetic traits outline vulnerability to cortical disruption in Parkinson's disease
NeuroImage: Clinical, Vol. 33
-
Teriflunomide-induced Raynaud’s phenomenon: a serious adverse event, previously unreported
Neurological Sciences
-
Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
Therapeutic Advances in Musculoskeletal Disease, Vol. 14
2021
-
Amyotrophic lateral sclerosis (ALS), cancer, autoimmunity and metabolic disorders: An unsolved tantalizing challenge
British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1269-1278
-
Clinical and preclinical evidence of somatosensory involvement in amyotrophic lateral sclerosis
British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1257-1268
-
Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study
Frontiers in Immunology, Vol. 12
-
European registry on helicobacter pylori management: Effectiveness of first and second-line treatment in Spain
Antibiotics, Vol. 10, Núm. 1, pp. 1-15
-
Long-term Follow-up and optimization of infliximab in refractory uveitis due to Behçet Disease: National study of 103 white patients
Journal of Rheumatology, Vol. 48, Núm. 5, pp. 741-750
-
Predictive value of prolactin in first episode psychosis at ten years follow-up
Revista de Psiquiatria y Salud Mental, Vol. 14, Núm. 3, pp. 179-180
-
Timing and characteristics of venous thromboembolism after noncancer surgery
Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 9, Núm. 4, pp. 859-867.e2
2020
-
A comprehensive serum lipidome profiling of amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 21, Núm. 3-4, pp. 252-262
-
A novel SGCE variant is associated with myoclonus-dystonia with phenotypic variability
Neurological Sciences, Vol. 41, Núm. 12, pp. 3779-3781